GenScript USA Inc

GenScript Biotech Corp. (HK Stock: 01548) is the world leader in the biotechnology reagent service industry. Established in 2002 in New Jersey, United States, the company was the first to commercialize gene synthesis and successfully establish fully integrated capabilities for custom peptide synthesis, protein expression and engineering, custom antibody development and engineering, animal model development, in vitro/in vivo pharmacology as well as a variety of catalogue products, industrial enzymes and microbial reagents.

Headquartered in Nanjing, China, GenScript has R&D, production and operation centers in both Nanjing, China, and New Jersey, U.S. manufacturing bases in Zhenjiang and Jinan, China, and operation branches in Ireland, Netherland, and Japan. To leverage its technology advantage in enzyme engineering and boost synthetic biology applications in microbial industry, GenScript has recently established a biocatalysis research institute in Shanghai. With these facilities, GenScript has been serving more than 200,000 customers in 100+ countries around the world for more than 16 years.

Since the first day, GenScript believed that "human and science engines" were the driving forces of its business. That is why among its 2600+ employees, by now there are more than 800 with master’s or Ph.D. degrees. This percentage is even higher than 90% in R&D and commercial teams. These powerful engines have enabled GenScript to develop and use the latest discoveries and technologies for establishing its fully integrated platforms towards generating industry-leading, highly customizable reagents for diverse applications.